cas 25952-53-8|| where to buy 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

Название продукции:1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

IUPAC Name:(3-{[(ethylimino)methylidene]amino}propyl)dimethylamine hydrochloride

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM303421-1000g	in stock	țǊɅ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 25952-53-8 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:25952-53-8; Молекулярная формула:C8H18ClN3; Точка плавления:-; Smiles-код:CCN=C=NCCCN(C)C.[H]Cl; Плотность:

: Номер в каталоге:CM303421; Молекулярная масса:191.7; Точка кипения:197.7°C at 760 mmHg; Номер Mdl:MFCD00012503; Хранение:Keep in a dry and a tight container and store at 2°C~8°C

: Momelotinib; GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.